Pyrimidine Compound Inducing p15 and p27 Proteins for Antitumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical agents lack effective antitumor activity and MEK inhibitory action, particularly in addressing undesirable cell proliferation and tumor growth, with existing compounds not adequately inducing p15 and p27 proteins to inhibit cancer cell proliferation.
Innovation Solution
A pyrimidine compound or its pharmaceutically acceptable salt, represented by specific formulas, is used as an active ingredient to induce p15 and/or p27 protein and exhibit MEK inhibitory action, thereby inhibiting undesirable cell proliferation and treating tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pharmaceutical agents are used, then general cell proliferation inhibition may be achieved, but effective antitumor activity and MEK inhibitory action are insufficient
Solution Approach 1:
The patent modifies the chemical structure of pyrimidine compounds by changing specific parameters (substituents at positions 4, 6, and N1) to achieve both potent antitumor activity and MEK inhibitory action. The structural optimization involves selecting specific R1-R6 groups that enhance the compound's ability to induce p15/p27 proteins while maintaining MEK inhibition capability.
2Productivity
If compounds that induce p15 and p27 proteins are developed, then cell proliferation inhibition is improved, but selective antitumor efficacy against various cancers remains insufficient
Solution Approach 1:
The pyrimidine compound is designed to perform multiple functions simultaneously: inducing p15 and p27 proteins, inhibiting MEK activity, and demonstrating broad-spectrum antitumor efficacy against various cancer types including colorectal, pancreatic, and lung cancers. This multi-functional design allows a single compound to address multiple aspects of cancer therapy.
3Measurement precision
If MEK inhibition is enhanced, then ERK1/2 activity suppression is improved, but broader Raf-MEK-ERK pathway coverage is reduced
Solution Approach 1:
The pyrimidine compound acts as an intermediary that indirectly suppresses the entire Raf-MEK-ERK pathway by inducing p15 and p27 proteins, which then inhibit CDK4/6 and subsequently reduce ERK1/2 activity. This intermediary mechanism allows broad pathway coverage while achieving precise suppression of downstream ERK1/2 activity.
Data Source
AI summary
The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I]wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like. In addition, the compound of the present invention can be a more effective antitumor agent when used in combination with other antitumor agents such as an alkylating agent or metabolism antagonist.